Blockchain Registration Transaction Record

Quantum BioPharma: Dual Push in MS and Alcohol Metabolism

Quantum BioPharma advances Lucid-MS for MS and unbuzzd supplement, targeting myelin repair and alcohol metabolism. Learn about their dual strategy and clinical progress.

This news matters because it highlights Quantum BioPharma's innovative approach to two significant health issues: multiple sclerosis and alcohol misuse. Lucid-MS's mechanism targeting PAD2 could offer a new treatment avenue for MS patients, potentially slowing or reversing disease progression. Meanwhile, unbuzzd addresses the widespread problem of hangovers and acute intoxication, with potential implications for public health and safety. For investors, the company's progress in clinical trials and commercialization could influence the biotech sector and offer opportunities for growth.